Mid-weight oncology stocks: The dark horses of cancer research
18 No. of Symbols
Next report date
Report period
Q1 2024
EPS estimate
−0.51USD
Revenue estimate
5.43 MUSD
−1.96USD
−112.96 MUSD
23.39 MUSD
66.14 M
About IDEAYA Biosciences, Inc.
Sector
CEO
Yujiro S. Hata
Headquarters
South San Francisco
Website
Employees (FY)
124
Founded
2015
FIGI
BBG00CTZ4D83
IDEAYA Biosciences, Inc. engages in the research and development of oncology-focused precision medicine. The firm focuses on the targeted therapeutics for patients selected using molecular diagnostics. Its product candidate, IDE196, is a protein kinase C inhibitor for genetically defined cancers having GNAQ or GNA11 gene mutations. The company was founded by Yujiro S. Hata and Jeffrey Hager in June 2015 and is headquartered in South San Francisco, CA.
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Curated watchlists where IDYA is featured.
Frequently Asked Questions
The current price of IDYA is 39.94 USD — it has increased by 3.42% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange IDEAYA Biosciences, Inc. stocks are traded under the ticker IDYA.
IDEAYA Biosciences, Inc. is going to release the next earnings report on May 7, 2024. Keep track of upcoming events with our Earnings Calendar.
IDYA stock is 5.90% volatile and has beta coefficient of 1.35. Check out the list of the most volatile stocks — is IDEAYA Biosciences, Inc. there?
IDYA earnings for the last quarter are −0.46 USD per share, whereas the estimation was −0.49 USD resulting in a 5.96% surprise. The estimated earnings for the next quarter are −0.47 USD per share. See more details about IDEAYA Biosciences, Inc. earnings.
IDEAYA Biosciences, Inc. revenue for the last quarter amounts to 8.04 M USD despite the estimated figure of 8.38 M USD. In the next quarter revenue is expected to reach 8.84 M USD.
Yes, you can track IDEAYA Biosciences, Inc. financials in yearly and quarterly reports right on TradingView.
IDYA stock has risen by 6.85% compared to the previous week, the month change is a 6.90% fall, over the last year IDEAYA Biosciences, Inc. has showed a 116.83% increase.
IDYA net income for the last quarter is −33.96 M USD, while the quarter before that showed −27.44 M USD of net income which accounts for −23.74% change. Track more IDEAYA Biosciences, Inc. financial stats to get the full picture.
Today IDEAYA Biosciences, Inc. has the market capitalization of 2.89 B, it has decreased by 8.70% over the last week.
No, IDYA doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, IDYA shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade IDEAYA Biosciences, Inc. stock right from TradingView charts — choose your broker and connect to your account.
As of Apr 26, 2024, the company has 124.00 employees. See our rating of the largest employees — is IDEAYA Biosciences, Inc. on this list?
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So IDEAYA Biosciences, Inc. technincal analysis shows the neutral today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating IDEAYA Biosciences, Inc. stock shows the buy signal. See more of IDEAYA Biosciences, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.
We've gathered analysts' opinions on IDEAYA Biosciences, Inc. future price: according to them, IDYA price has a max estimate of 60.00 USD and a min estimate of 50.00 USD. Read a more detailed IDEAYA Biosciences, Inc. forecast: see what analysts think of IDEAYA Biosciences, Inc. and suggest that you do with its stocks.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. IDEAYA Biosciences, Inc. EBITDA is −130.46 M USD, and current EBITDA margin is −557.71%. See more stats in IDEAYA Biosciences, Inc. financial statements.